| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.01701105 |
| P698 | PubMed publication ID | 17699296 |
| P50 | author | Stanley C Jordan | Q96350303 |
| P2093 | author name string | Kai Yang | |
| Alice Peng | |||
| Mieko Toyoda | |||
| Suphamai Bunnapradist | |||
| Ashley A Vo | |||
| Dechu P Puliyanda | |||
| Marina Lukovsky | |||
| Vinh Cam | |||
| P433 | issue | 4 | |
| P304 | page(s) | 844-852 | |
| P577 | publication date | 2006-04-26 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience | |
| P478 | volume | 1 |
| Q45326944 | A Case Report of Recurrent Takotsubo Cardiomyopathy in a Patient during Myasthenia Crisis. |
| Q41118002 | Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management |
| Q33560520 | Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q57482179 | Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases |
| Q35545777 | Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology |
| Q37984565 | Biological agents for the treatment of uveitis |
| Q37827197 | Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients |
| Q26863564 | Desensitization for solid organ and hematopoietic stem cell transplantation |
| Q34767262 | Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. |
| Q46048428 | Dosing and therapy utilization: a discussion of updates on PI treatment guidelines |
| Q46004431 | Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. |
| Q39944805 | High dose intravenous immunoglobulin may be complicated by myocardial infarction. |
| Q36843406 | High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients |
| Q34484801 | Immunosuppressive Medications |
| Q38111424 | Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects |
| Q38614953 | Managing patients with side effects and adverse events to immunoglobulin therapy |
| Q38029244 | Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again |
| Q51768759 | Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. |
| Q44077279 | Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy |
| Q37931231 | Special considerations with the use of intravenous immunoglobulin in older persons |
| Q39207717 | Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus |
Search more.